Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects
NCT00829777
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
8
Enrollment
OTHER
Sponsor class
Conditions
Opiate Addiction
Interventions
DRUG:
6β-Naltrexol escalating doses from 0.05-0.5 mg IV
Sponsor
California Pacific Medical Center Research Institute